NCT06271057 is a Phase 2 clinical trial of golcadomide in Diffuse Large B-cell Lymphoma Refractory, sponsored by The Lymphoma Academic Research Organisation.

Who is sponsoring NCT06271057?

NCT06271057 is sponsored by The Lymphoma Academic Research Organisation.

What drugs are being tested in NCT06271057?

Interventions in NCT06271057: golcadomide.

What condition does NCT06271057 study?

NCT06271057 studies Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma.

Is NCT06271057 still recruiting?

NCT06271057 is currently recruiting now. Last updated 15 October 2024.

Last reviewed 2024-10-15 · How we verify

NCT06271057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Recruiting now Phase 2 Last updated 15 October 2024

What this trial tests

Phase 2 trial testing golcadomide in Diffuse Large B-cell Lymphoma Refractory in 65 participants. Currently enrolling.

Timeline

14 June 2024

Primary endpoint
15 January 2026

20 October 2027

Quick facts

Lead sponsor	The Lymphoma Academic Research Organisation
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	14 June 2024
Primary completion	15 January 2026
Estimated completion	20 October 2027
Sites	13 locations across France

Drugs / interventions tested

golcadomide — full drug profile →

Conditions studied

Diffuse Large B-cell Lymphoma Refractory — all drugs for Diffuse Large B-cell Lymphoma Refractory →
Refractory Primary Mediastinal Large B-Cell Lymphoma — all drugs for Refractory Primary Mediastinal Large B-Cell Lymphoma →
Refractory Transformed B-cell Non-Hodgkin Lymphoma — all drugs for Refractory Transformed B-cell Non-Hodgkin Lymphoma →
Refractory High Grade B-Cell Lymphoma — all drugs for Refractory High Grade B-Cell Lymphoma →

Sponsor

The Lymphoma Academic Research Organisation — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-cell Lymphoma Refractory or Refractory Primary Mediastinal Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first. Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study. The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion. The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
2026 Update on the Management of Diffuse Large B-Cell Lymphoma.
Chong EA, Tomasulo EB, Barta SK. · · 2026 · PMID 41654318 · DOI 10.1002/ajh.70229

Verify or expand the search:

Other trials of golcadomide

Trials testing the same drug.

NCT05788081 — Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. · Phase 2 · active not recruiting

Other The Lymphoma Academic Research Organisation trials

Trials by the same sponsor.

NCT06994169 — Glofitamab in Real Life · recruiting
NCT06592846 — FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up · completed
NCT05529524 — Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) · completed
NCT04802590 — Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · Phase 2 · active not recruiting
NCT04974216 — Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06271057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Lymphoma Academic Research Organisation
Last refreshed: 15 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06271057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing